Chief Executive Officer and Co-Founder, BioVersys AG
Appears in 1 story
Leading BV100 through Phase 3 development
No genuinely new class of antibiotic has reached patients since 1987. In the nearly four decades since, bacteria have steadily evolved resistance to existing drugs, and carbapenem-resistant Acinetobacter baumannii—a hospital-acquired pathogen that kills up to 60 percent of ventilated pneumonia patients—now sits atop the World Health Organization's list of critical-priority threats. On March 16, 2026, Swiss biotech BioVersys received clearance from the United States Food and Drug Administration (FDA) to begin enrolling American patients in a Phase 3 pivotal trial of BV100, a drug that cut 28-day mortality in half during earlier testing.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
